A Phosphatidyl Conjugated Telomerase-Dependent Telomere-Targeting Nucleoside Demonstrates Colorectal Cancer Direct Killing and Immune Signaling
Biomolecules · 2024
DOI: 10.3390/biom14121616 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2024. Verfasst von Merve Yilmaz und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biochemistry, Faculty of Medicine, Hacettepe University, Ankara 06100, Turkey. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Telomerase, Telomere. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, MAIA Biotechnology.
Abstract (Originalsprache)
Telomerase and telomeres are crucial in cancer cell immortalization, making them key targets for anticancer therapies. Currently, 6-thio-dG (THIO) combined with the anti-PD-1 inhibitor Cemiplimab is under phase II clinical investigation (NCT05208944) in NSCLC patients resistant to prior immunotherapies. This study presents the design, synthesis, and evaluation of novel bimodular conjugate molecules combining telomere-targeting nucleoside analogs and phosphatidyl diglyceride groups. Among them, dihexanoyl-phosphatidyl-THIO (diC6-THIO) showed high anticancer activity with sub-µM EC50 values in vitro across various cancer cell lines. In mouse colorectal cancer models, diC6-THIO demonstrated strong anticancer effects alone and in combination with PD1/PD-L1 inhibitors. Administration of this compound resulted in the efficient formation of Telomere dysfunction Induced Foci (TIFs) in vitro, indicating an on-target, telomerase-mediated telomere-modifying mechanism of action for the molecule. Systemic treatment also activated CD4+ and CD8+ T cells while reducing regulatory T cells, indicating immune system enhancement. Notably, diC6-THIO exhibits an improved solubility profile while maintaining comparable anticancer properties, further supporting its potential as a promising therapeutic candidate. These findings highlight diC6-THIO as a promising telomere-targeting prodrug with dual effects on telomere modification and immune activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biochemistry, Faculty of Medicine, Hacettepe University, Ankara 06100, Turkey.
- Department of Cell Biology, UT Southwestern Medical Center, Dallas, TX 75390, USA.
- Department of Medical and Surgical Research, Institute of Health Sciences, Hacettepe University, Ankara 06100, Turkey.
- MAIA Biotechnology, Inc., Chicago, IL 60606, USA.
- Department of Basic Oncology, Cancer Institute, Hacettepe University, Ankara 06100, Turkey.
- Neurological and Psychiatric Research and Application Center, Faculty of Medicine, Hacettepe University, Ankara 06100, Turkey.
ORCID-Profile: Sibel Goksen, Ilgen Mender, Ates Kutay Tenekeci, Sergei M Gryaznov, Jerry W Shay, Z Gunnur Dikmen
Förderung
- NCI NIH HHS
- NIH HHS
- MAIA Biotechnology
Zitieren
APA
Yilmaz, M., Goksen, S., Mender, I., Esendagli, G., Erdener, S. E., Ahmed, A., Tenekeci, A. K., Birichevskaya, L. L., Gryaznov, S. M., Shay, J. W., & Dikmen, Z. G. (2024). A Phosphatidyl Conjugated Telomerase-Dependent Telomere-Targeting Nucleoside Demonstrates Colorectal Cancer Direct Killing and Immune Signaling. Biomolecules. https://doi.org/10.3390/biom14121616
Vancouver
Yilmaz M, Goksen S, Mender I, Esendagli G, Erdener SE, Ahmed A, et al. A Phosphatidyl Conjugated Telomerase-Dependent Telomere-Targeting Nucleoside Demonstrates Colorectal Cancer Direct Killing and Immune Signaling. Biomolecules. 2024. doi:10.3390/biom14121616
BibTeX
@article{Yilmaz2024,
author = {Yilmaz, Merve and Goksen, Sibel and Mender, Ilgen and Esendagli, Gunes and Erdener, Sefik Evren and Ahmed, Alessandra and Tenekeci, Ates Kutay and Birichevskaya, Larisa L and Gryaznov, Sergei M and Shay, Jerry W and Dikmen, Z Gunnur},
title = {A Phosphatidyl Conjugated Telomerase-Dependent Telomere-Targeting Nucleoside Demonstrates Colorectal Cancer Direct Killing and Immune Signaling},
journal = {Biomolecules},
year = {2024},
doi = {10.3390/biom14121616}
}
EUVIMED